commercial partnership
We provide hope where no one else does
commecial partnership
We provide hope where no one else does!
FarmaMondo is a full commercial partner for biopharma companies seeking to enter emerging markets across our vast footprint.
We extend and broaden product life cycles, improving patient access and maximizing market reach.
Our Approach
We follow a phased, market-tailored strategy to optimize regulatory and reimbursement pathways, unlocking the full potential of our partners’ innovative products.
We are a flexible, pragmatic, and patient-focused partner, committed to delivering strong commercial performance for innovative therapies.
Our 14 international locations deliver our commercial capabilities across key emerging markets in 5 regions
Latin America
Asia Pacific
India
Middle East North Africa
Russia & CIS
Our 13 international locations
deliver our commercial capabilities across key emerging markets in 5 regions
Latin America
Asia Pacific
India
Middle East North Africa
Russia & CIS
Our scalable, full-service structure is locally adapted and centrally governed. We engage directly – country by country – with KOLs, HCPs, centres of excellence, patient advocacy groups, payors, charities, and regulators.
Examples of various partnerships and experiences across various therapeutic areas:
| Therapeutic Area | Indication | Geographical Scope |
|---|---|---|
| Oncology | ESR1 Mutated Breast Cancer | Emerging Markets |
| Adrenocortical Carcinoma (ACC) | Regional/Cluster | |
| Wilm’s Tumor | Regional/Cluster | |
| Haemato-oncology | High Risk Neuroblastoma (HRNB) | Emerging Markets |
| Acute Lymphoblastic Leukemia (ALL) | Emerging Markets | |
| Metabolic Disease Orphan | Alagille Syndrome (ALGS) | Regional/Cluster |
| Congenital or Acquired Generalized Lipodystrophy (GL) | Regional/Cluster | |
| Homozygous Familial Hypercholesterolemia | Regional/Cluster | |
| Progressive Familial Intrahepatic Cholestasis (PFIC) | Regional/Cluster | |
| Neurology Orphan | Allan Herndon Dudley Syndrome (MCT8 Deficiency) | Regional/Cluster |
| Duchenne Muscular Dystrophy | Regional/Cluster | |
| Rett Syndrome | Emerging Markets | |
| Immunology Orphan | Multicentric Castelman Disease | Emerging Markets |
| Dermatology Orphan | Epidermolysis Bullosa (EB) | Regional/Cluster |
| Ophthalmology Orphan | Neurotrophic Keratitis | Emerging Markets |
| Therapeutic Area | Indication | Geographical Scope |
|---|---|---|
| Oncology | ESR1 Mutated Breast Cancer | Emerging Markets |
| Andrenocortical Carcinoma (ACC) | Regional/Cluster | |
| Wilm’s Tumor | Regional/Cluster | |
| Haemato-oncology | High Risk Neuroblastoma (HRNB) | Emerging Markets |
| Acute Lymphoblastic Leukemia (ALL) | Emerging Markets | |
| Metabolic Disease Orphan | Alagille Syndrome (ALGS) | Regional/Cluster |
| Congenital or Acquired Generalized Lipodystrophy (GL) | Regional/Cluster | |
| Homozygous Familial Hypercholesterolemia | Regional/Cluster | |
| Progressive Familial Intrahepatic Cholestasis (PFIC) | Regional/Cluster | |
| Neurology Orphan | Allan Herndon Dudley Syndrome (MCT8 Defficiency) | Regional/Cluster |
| Duchenne Muscular Dystrophy | Regional/Cluster | |
| Rett Syndrome | Emerging Markets | |
| Immunology Orphan | Multicentric Castelman Disease | Emerging Markets |
| Dermatology Orphan | Epidermolysis Bullosa (EB) | Regional/Cluster |
| Ophthalmology Orphan | Neurotrophic Keratitis | Emerging Markets |
